2012-09-17 07:20:15 - New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research

Global Markets Direct's, 'Clostridium Botulinum Infections - Pipeline Review, H2 2012', provides an overview of the Clostridium Botulinum Infections therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Botulinum Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Botulinum Infections. 'Clostridium Botulinum Infections - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and

relevance of data for the indicated disease.


Full Report Details at
- www.fastmr.com/prod/463798_clostridium_botulinum_infections_pipe ..


Scope

* A snapshot of the global therapeutic scenario for Clostridium Botulinum Infections.
* A review of the Clostridium Botulinum Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Clostridium Botulinum Infections pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Clostridium Botulinum Infections.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Clostridium Botulinum Infections pipeline depth and focus of Clostridium Botulinum Infections therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Clostridium Botulinum Infections Therapeutic Products under Development, Key Players in Clostridium Botulinum Infections Therapeutics, Clostridium Botulinum Infections Pipeline Overview, Clostridium Botulinum Infections Pipeline, Clostridium Botulinum Infections Pipeline Assessment

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Clostridium Botulinum Infections Overview
Therapeutics Development
An Overview of Pipeline Products for Clostridium Botulinum Infections
Clostridium Botulinum Infections Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Clostridium Botulinum Infections Therapeutics - Products under Development by Companies
Companies Involved in Clostridium Botulinum Infections Therapeutics Development
Emergent BioSolutions Inc.
Cangene Corporation
XOMA Ltd.
Morphotek, Inc.
AlphaVax, Inc.
DynPort Vaccine Company LLC
Molecular Targeting Technologies, Inc.
Clostridium Botulinum Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
MORAb-047 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Botulinum Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Botulinum Toxin Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XOMA 3AB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Botulism Antitoxin Heptavalent - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rBV A/B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Botulinum Toxin Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Clostridium Botulinum Infections Therapeutics - Drug Profile Updates
Clostridium Botulinum Infections - Product Development Milestones
Featured News & Press Releases
May 03, 2011: XOMA 3AB, New Triple-Antibody Anti-Botulinum Neurotoxin Product, Enters Phase I Clinical Testing
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Clostridium Botulinum Infections, H2 2012

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=463798&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.